395, no persons are required

PTO/SB:08A (08-CO) Approved for use through 10/31/2002. OMB C651-C031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

> (use as many sheets as necessary) Sheet 1 of 1

to respond to a collection of information unit	ess il dispiays a valio U.V.B contro. number.		
Confirmation Number	2156		
Application Number	10/811,292		
Filing Date	03/26/2004		
First Named Inventor	Brett Allison		
Group Art Unit	1614 1626		
Examiner Name			
Attorney Docket Number	PRD2053		

						y Docket Number	PRD2053	
		IIS Pat	ent Document		U.S. PATENT DOCUMENTS			
Exam Initials	Cite No.'	Kind Code ^z Number (if known)		Name of Patentee or Applican of Cited Document	Date of Publication of Cited Documents		ages c	
76		5,534	,530	Α	Frehel et al.	07-09-1996		
					FOREIGN PATENT DOCUMENT			
Exam Initials	aa		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear			
\top	No.1	EP	0 620 221	A1	Elf Sanofl	10-19-1994	US5534530	No
		wo	02/42248	A2	Novartis AG	05-30-2002		
V		wo	02/90353	A1	Amithkline Beecham Cor	p. 11-14-2002		
			OTHE	PRIOR	ART - NON PATENT LITERATUR	RE DOCUMENTS		<u>i </u>
Exam Initials	Cite No.1	Includige journal,	de name of the auth	or (in CAF	PITAL LETTERS), title of the article (white.), date, page(s), volume-issue numb	nen appropriate), title of the	item (book, magazine, country where published	Т
								+
		1						1

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered


8

o la

Signature

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, OC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. s Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.



Confirmation Number	2156				
Application Number	10/811,292				
Filing Date	03/26/2004				
First Named Inventor	Brett Allison				
Group Art Unit	1614 626				
Examiner Name					
Attorney Docket Number	PRD2053				

FOREIGN PATENT DOCUMENTS Foreign Patent Document Pages, Columns, Lines, where relevant passages Name of Patentee or Examiner Cite or relevant figures **Applicant of Cited Document** Initials Office³ Number⁴ KindCode⁵ appear No.1 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), Cite No.1 Examiner T² volume-issue number(s), publisher, city and/or country where published Initials* International Search Report dated March 15, 2005, for corresponding international application PCT/US2004/009589.

Examiner Signature	I. A.	Sololos	Date Considered	7-18-06

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0551-0331
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO
Application Number 10/811,292

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

and not considered. Include copy of this form with next communication to applicant.

possible. 6 Applicant is to place a check mark here if English language Translation is attached.

a concension of intermation unless it displays a	A Valid Civio Coridor Humbor.				
Application Number	10/811,292				
Filing Date	March 26, 2004				
First Named Inventor	Brett Allison				
Group Art Unit	1814 1626				
Examiner Name					
Attorney Docket Number	PRD2053USNP				

	T	U.S. Patent Do	cumont	U.S. PATENT DOCUMENTS		
Examiner Initials	1	U.S. Palent Do		Name of Patentee or Applicant	Date of Publication	Pages, Columns, Lines,
	Cite No. ¹	Number	Kind Code ² (if known)	of Cited Document	of Cited Document mm-dd-yyyy	where relevant passages o relevant figures appear
70		6,239,131		Shinozaki, K., et al.(Zeria Pharmaceutical Co., Ltd.	05-29-2001	
	<u> </u>					
				•		

FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Publication Pages, Columns, Lines, of Cited Document where relevant Name of Patentee or Examiner Cite passages or relevant T6 Applicant of Cited Document mm-dd-yyyy Initials figures appear Office³ Number⁴ KindCode⁵ No.1 WO 04013087 Makovec, F. et al. (Rotta Research 02-12-2004 70 Laboratorium)

Examiner Signature	1	· A.	So	06	Date Considere	18-0	6
- *EXAMINER	: Initial if refere	ence conside	ered, wheth	er or not o	itation is in conformance with MPEP 609.	Draw line through citation if not	in conformance

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute TRADEMARTH or form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a collection of information unless it displays	8 Valle Onto Conson Itumber.				
Application Number	10/811,292				
Filing Date	March 26, 2004				
First Named Inventor	Brett Allison				
Group Art Unit	1614 16 26				
Examiner Name					
Attorney Docket Number	PRD2053USNP				
	ı				

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
70		Black, J.W. and S.B. Kalindjian. Gastrin Agonists and Antagonists. Pharmacol. Toxicol. (2002) 91:275-281.	<u> </u>
		de Tullio, P. et al. Therapeutic and Chemical Developments of Cholecystokinin Receptor Ligands. Exp. Opin. Invest. Drugs (2000) 9(1):129-146.	
		Herranz, R. Cholecystokinin Antagonists: Pharmacological and Therapeutic Potential. Med. Res. Rev. (2003) 23(5):559-605.	
		Revel, L. and F. Makovec, Update on Nonpeptide CCK-B Receptor Antagonists, Drugs Future, (1998) 23(7):751-766.	
		McDonald, I.M. CCK2 Receptor Antagonists. Exp. Opin. Ther. Patents. (2001) 11(3):445-462.	
		Morton, M.F. et al. Pharmacological Comparison of the Alternatively Spliced Short and Long CCK2 Receptors. Br. J. Pharmacol. (2003) 140(1):218-224.	
		Tracy, H.J. and R.A. Gregory. Physiological Properties of a Series of Peptides Structurally Related to Gastrin 1. Nature (London). (1964) 204:935-938.	
		Varnavas, A. et al. Anthranilic Acid Based CCK1 Antagonists: The 2-Indole Moiety May Represent a "Needle" According to the Recent Homonymous Concept. Eur. J. Med. Chem. (2004) 39:85-97.	
		Varnavas, A. et al. Anthranilic Acid Derivatives: A New Class of Non-Peptide CCK1 Receptor Antagonists. Bioorg. Med. Chem. (2003) 11:741-751.	
V		Varnavas, A. et al. Synthesis of N-Terminal Substituted Anthranilic Acid Dimer Derivatives for Evaluation on CCK Receptors. Il Farmaco. (2001) 56:555-564.	
·			
	-		
			ļ

Examiner	 _ ^	اسر	/ /	Date	- 10 -1	
2.1	Ι. Δ	. < 21	n/a.		1-19-06	
Signature		ں۔۔	$O \cup A$	Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.